Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Modified bi-weekly cetuximab-cisplatin and 5-FU/leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients.
Meirovitz A, Bergerson S, Hirshoren N, Weinberger JM, Bersudski E, Daniel S, Sheva K, Perez CA. Meirovitz A, et al. Among authors: sheva k. Cancer Rep (Hoboken). 2022 Mar;5(3):e1479. doi: 10.1002/cnr2.1479. Epub 2021 Jun 28. Cancer Rep (Hoboken). 2022. PMID: 34184405 Free PMC article.
Computational quantification and characterization of independently evolving cellular subpopulations within tumors is critical to inhibit anti-cancer therapy resistance.
Alkhatib H, Rubinstein AM, Vasudevan S, Flashner-Abramson E, Stefansky S, Chowdhury SR, Oguche S, Peretz-Yablonsky T, Granit A, Granot Z, Ben-Porath I, Sheva K, Feldman J, Cohen NE, Meirovitz A, Kravchenko-Balasha N. Alkhatib H, et al. Among authors: sheva k. Genome Med. 2022 Oct 20;14(1):120. doi: 10.1186/s13073-022-01121-y. Genome Med. 2022. PMID: 36266692 Free PMC article.
Molecular Changes in Breast Cancer Induced by Radiation Therapy.
Sheva K, Roy Chowdhury S, Kravchenko-Balasha N, Meirovitz A. Sheva K, et al. Int J Radiat Oncol Biol Phys. 2024 Mar 18:S0360-3016(24)00435-8. doi: 10.1016/j.ijrobp.2024.03.019. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 38508467 Review.
Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response.
Mizrahi AG, Hamad H, Gugenheim A, Nisman B, Kuznetz A, David IB, Gelfend Y, Cohen S, Zick A, Sheva K, Nechushtan H, Peretz T, Meirovitz A. Mizrahi AG, et al. Among authors: sheva k. Anticancer Res. 2022 Nov;42(11):5257-5263. doi: 10.21873/anticanres.16032. Anticancer Res. 2022. PMID: 36288893